The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Monitoring patients with CLL on ibrutinib-based therapies
Jan Burger, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the long-term treatment of patients with BTK inhibitors like ibrutinib, emphasizing the importance of monitoring quality of life and side effects. He highlights the rarity of treatment resistance and notes the need for frequent check-ups to assess cardiovascular side effects. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: AstraZeneca, BeiGene, Abbvie; Speaker Fees: Janssen.
